Timing of recurrent venous thromboembolism early after the index event: A meta-analysis of randomized controlled trials

Thrombosis Research

Volumn 132, Issue 4, 2013, Pages 420-426

  Limone, Brendan L ^a,b   Hernandez, Adrian V ^c,d   Michalak, Daniel ^a   Bookhart, Brahim K ^e   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d INSTITUTO NACIONAL DE SALUD   (Peru)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anticoagulants; Deep vein thrombosis; Meta analysis; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; ENOXAPARIN; HEPARIN; IDRABIOTAPARINUX; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; RIVAROXABAN; TINZAPARIN; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTICLE; CANCER PATIENT; DEEP VEIN THROMBOSIS; EMBASE; HUMAN; LUNG EMBOLISM; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RECURRENT VENOUS THROMBOEMBOLISM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VALIDITY; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DEEP VEIN THROMBOSIS; META-ANALYSIS; PULMONARY EMBOLISM; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DISEASE PROGRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84885172316     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.08.003     Document Type: Article

References (29)

1. F.A. Spencer, C. Emery, D. Lessard, F. Anderson, S. Emani, and J. Aragam The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism J Gen Intern Med 21 2006 722 727
2. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, and S.Z. Goldhaber Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e419S-94S
3. J.D. Douketis, G.A. Foster, M.A. Crowther, M.H. Prins, and J.S. Ginsberg Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy Arch Intern Med 160 2000 3431 3436
4. The Columbus Investigators Low-molecular-weight heparin in the treatment of patients with venous thromboembolism N Engl J Med 337 1997 657 662
5. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, and D.J. Gavaghan Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
6. M.K. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
7. P.R. Williamson, C.T. Smith, J.L. Hutton, and A.G. Marson Aggregate data meta-analysis with time-to-event outcomes Stat Med 21 2002 3337 3351
8. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, and M.R. Sydes Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 2007 16
9. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006] J.P.T. Higgins, and S. Green The Cochrane Library Issue 4 2006 John Wiley & Sons, Ltd Chichester, UK
10. J.M. Bland, and D.G. Altman Applying the right statistics: analyses of measurement studies Ultrasound Obstet Gynecol 22 2003 85 93
11. D. Moher, A. Liberati, and J. Tetzlaff Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 21 2009 6 [e1000097]
12. H.R. Büller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, and E. Minar Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
13. H.R. Büller, A.S. Gallus, G. Pillion, M.H. Prins, G.E. Raskob, and Cassiopea Investigators Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial Lancet 379 2012 123 129
14. Equinox Investigators Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis J Thromb Haemost 9 2011 92 99
15. EINSTEIN Investigators, R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, and H. Decousus Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
16. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
17. van Gogh Investigators, H.R. Buller, A.T. Cohen, B. Davidson, H. Decousus, and A.S. Gallus Idraparinux versus standard therapy for venous thromboembolic disease N Engl J Med 357 2007 1094 1104
18. R.D. Hull, G.F. Pineo, R.F. Brant, A.F. Mah, N. Burke, and R. Dear Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms Am J Med 120 2007 72 82
19. J.N. Fiessinger, M.V. Huisman, B.L. Davidson, H. Bounameaux, C.W. Francis, and H. Eriksson Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial JAMA 293 2005 681 689
20. L. Pinede, J. Ninet, P. Duhaut, S. Chabaud, S. Demolombe-Rague, and I. Durieu Investigators of the "Durée Optimale du Traitement AntiVitamines K" (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis Circulation 103 2001 2453 2460
21. S. Schulman, A.S. Rhedin, P. Lindmarker, A. Carlsson, G. Lärfars, and P. Nicol A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group N Engl J Med 332 1995 1661 1665
22. H.K. Breddin, V. Hach-Wunderle, R. Nakov, V.V. Kakkar, and CORTES Investigators Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis N Engl J Med 344 2001 626 631
23. G. Merli, T.E. Spiro, C.G. Olsson, U. Abildgaard, B.L. Davidson, and A. Eldor Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease Ann Intern Med 134 2001 191 202
24. B.A. Charbonnier, J.N. Fiessinger, J.D. Banga, E. Wenzel, P. d'Azemar, and L. Sagnard Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group Thromb Haemost 79 1998 897 901
25. R.D. Hull, G.E. Raskob, G.F. Pineo, D. Green, A.A. Trowbridge, and C.G. Elliott Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis N Engl J Med 326 1992 975 982
26. C.I. Coleman, S.M. Coleman, J. Vanderpoel, W. Nelson, J.A. Colby, and J.M. Scholle Factors associated with 'caregiver burden' for atrial fibrillation patients Int J Clin Pract 66 2012 984 990
27. P.M. Erkens, H. ten Cate, H.R. Büller, and M.H. Prins Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis PLoS One 7 2012 e42269
28. W.L. Baker, D.A. Cios, S.D. Sander, and C.I. Coleman Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 15 2009 244 252
29. C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A.J. Forster Effect of study setting on anticoagulation control: a systematic review and metaregression Chest 129 2006 1155 1166